Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908076 · ClinicalTrials.gov registry record · Phase 4
Amitiza in Constipation Associated With PD (Parkinson's Disease)
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT00908076 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 78 participants.
The verdict
NCT00908076, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Amitiza (lubiprostone), a drug proven to be safe and effective for chronic constipation, will also improve constipation symptoms in Parkinson's Disease patients. We will also evaluate the impact of the drug on changes in bowel movement consistency, quality of life and motor symptoms.
Interventions
- DRUG LUBIPROSTONE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908076
The ClinicalTrials.gov registry entry for NCT00908076 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUBIPROSTONE is the first listed.
NCT00908076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908076 about?
NCT00908076 is a clinical study titled "Amitiza in Constipation Associated With PD (Parkinson's Disease)". The purpose of this study is to determine if Amitiza (lubiprostone), a drug proven to be safe and effective for chronic constipation, will also improve constipation symptoms in Parkinson's Disease patients. We will also evaluate the impact of the drug on changes in bowel movement consistency, qualit...
What is the current status of trial NCT00908076?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2009-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00908076?
The interventions under investigation include: LUBIPROSTONE (DRUG).
Who is sponsoring clinical trial NCT00908076?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.